BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36729147)

  • 41. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.
    Jiang M; Zhang H; Jiang Y; Yang Q; Xie L; Liu W; Zhang W; Ji X; Li P; Chen N; Zhao S; Wang F; Zou L
    Cancer; 2012 Jul; 118(13):3294-301. PubMed ID: 22139825
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A controlling nutritional status score is an independent predictor for patients with newly diagnosed nasal-type extranodal NK/T-cell lymphoma based on asparaginase-containing regimens.
    Wu W; Ren K; Chen X; Li N; Zhou H; Jiang M; Yu Y; Zou L
    Cancer Med; 2023 Apr; 12(8):9439-9448. PubMed ID: 36866811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
    Haverkos BM; Pan Z; Gru AA; Freud AG; Rabinovitch R; Xu-Welliver M; Otto B; Barrionuevo C; Baiocchi RA; Rochford R; Porcu P
    Curr Hematol Malig Rep; 2016 Dec; 11(6):514-527. PubMed ID: 27778143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
    Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
    Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
    Kim SJ; Yang DH; Kim JS; Kwak JY; Eom HS; Hong DS; Won JH; Lee JH; Yoon DH; Cho J; Nam TK; Lee SW; Ahn YC; Suh C; Kim WS
    Ann Hematol; 2014 Nov; 93(11):1895-901. PubMed ID: 24947798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical Characteristics and Prognostic Analysis of Extranodal NK/T-Cell Lymphoma Patients Treated with Pegaspargase Based Chemotherapy].
    Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):735-740. PubMed ID: 34105466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extranodal NK/T-cell lymphoma in Tunisia: clinicopathological features, immunophenotype and EBV infection.
    Missaoui N; Mestiri S; Bouriga A; Abdessayed N; Belakhdher M; Ghammem M; Abdelkefi M; Mokni M; Hmissa S
    J Egypt Natl Canc Inst; 2019 Oct; 31(1):1. PubMed ID: 32372136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
    Zheng W; Gao Y; Ke X; Zhang W; Su L; Ren H; Lin N; Xie Y; Tu M; Liu W; Ping L; Ying Z; Zhang C; Deng L; Wang X; Song Y; Zhu J
    BMC Cancer; 2018 Sep; 18(1):910. PubMed ID: 30241515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
    Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
    Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.
    Zang J; Li C; Luo SQ; Wang JH; Xu M; Zhao LN; Li WW; Yang H; Xiao F; Hitchcock YJ; Shi M
    Ann Hematol; 2015 Apr; 94(4):583-91. PubMed ID: 25409913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma.
    Liu JX; Liu X; Yang Y; Liu WP; Wang Y; He X; Zhang LL; Qu BL; Qian LT; Hou XR; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Zhang HL; Su H; Zhang YJ; Zhu J; Qi SN; Li YX; Song YQ
    Cancer Rep (Hoboken); 2023 May; 6(5):e1800. PubMed ID: 36919649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?
    Kim SJ; Oh SY; Hong JY; Chang MH; Lee DH; Huh J; Ko YH; Ahn YC; Kim HJ; Suh C; Kim K; Kim WS
    Ann Oncol; 2010 May; 21(5):1058-63. PubMed ID: 19850636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.
    Kim SJ; Park S; Kang ES; Choi JY; Lim DH; Ko YH; Kim WS
    Ann Hematol; 2015 Jan; 94(1):71-8. PubMed ID: 25082384
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dynamic evaluation of the prognostic value of
    Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
    Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Analysis of Clinical Efficacy and Influencing Factors of Gemcitabine-L-Asparaginase-Oxaliplatin Chemotherapy Scheme and Radiotherapy for Treatment of Early ENKTL Patients].
    Qiu C; Wang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1420-1425. PubMed ID: 29070118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
    Jaccard A; Gachard N; Marin B; Rogez S; Audrain M; Suarez F; Tilly H; Morschhauser F; Thieblemont C; Ysebaert L; Devidas A; Petit B; de Leval L; Gaulard P; Feuillard J; Bordessoule D; Hermine O;
    Blood; 2011 Feb; 117(6):1834-9. PubMed ID: 21123825
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma.
    Jing XM; Zhang ZH; Wu P; Zhang SC; Ren YR; Xiong ZJ; Wei W; Luo L; Li L
    Leuk Res; 2016 Aug; 47():26-31. PubMed ID: 27239738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome.
    Jia J; Song Y; Lin N; Liu W; Ping L; Zheng W; Wang X; Xie Y; Tu M; Zhang C; Ying Z; Deng L; Ding N; Zhu J
    Ann Hematol; 2016 Dec; 95(12):2023-2031. PubMed ID: 27595760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
    Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.